Key result
Novel KV7 channel opener S-35 demonstrates robust antiseizure efficacy and favorable pharmacokinetics in rodents.
Why the study?
There has been strong interest in developing neuronal KV7 potassium channel openers, especially KV7.2 and KV7.3, given evidence supporting their therapeutic potential in seizure disorders.
Population
Preclinical species and rodents
Design
Preclinical drug discovery and rodent AC-MES assay study
Authors
Loading...
Hypothesis-generating for novel KV7 potassium channel openers in seizure management; leaves open.
The novel bicyclic pyrazole amide S-35 shows promise as a potent neuronal KV7 potassium channel opener with strong preclinical antiseizure activity.
Sun et al. (2026) studied Seizure disorders. S-35 was evaluated on Antiseizure efficacy in rodent alternating-current maximal electroshock seizure (AC-MES) assays. S-35, a novel bicyclic pyrazole amide and potent neuronal KV7 potassium channel opener, demonstrated favorable pharmacokinetics and robust antiseizure efficacy in preclinical rodent models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: